Ovarian epithelial cancer stage IV

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
PARP inhibitor 1 substance
Phase IV: 1 Phase I (First in Human): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase IV

1 trial
  • Mario Negri Institute For Pharmacological Research Academic
    OLAPARIB
    2022-502242-27-00 1 country 2023 n=190
    Ended

Phase I (First in Human)

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Mario Negri Institute For Pharmacological Research Academic 1 Phase IV 0
New trials by year
2023
1
2025
1
← All indication landscapes